Summary of Significant Accounting Policies - Schedule of Financial Assets and Liabilities Measured and Recognized at Fair Value (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Assets:
Investments			$ 6,030
Acquisition rights of Enalare Therapeutics, Inc.	$ 8,125
Money market funds			57,357
Convertible promissory note			4,021
Embedded derivative asset in convertible promissory note			962
Liability:
Forward Liability	4,063
Investment in Syros Pharmaceuticals, Inc. ("Syros")
Assets:
Investments	2,882
Investment in Enalare Therapeutics, Inc.
Assets:
Investments	8,438	$ 0
Acquisition rights of Enalare Therapeutics, Inc.	8,125	0
Liability:
Forward Liability	4,063	$ 0
Level 1
Assets:
Investments			6,030
Acquisition rights of Enalare Therapeutics, Inc.	0
Money market funds			57,357
Convertible promissory note			0
Embedded derivative asset in convertible promissory note			0
Liability:
Forward Liability	0
Level 1 | Investment in Syros Pharmaceuticals, Inc. ("Syros")
Assets:
Investments	2,882
Level 1 | Investment in Enalare Therapeutics, Inc.
Assets:
Investments	0
Level 2
Assets:
Investments			0
Acquisition rights of Enalare Therapeutics, Inc.	0
Money market funds			0
Convertible promissory note			0
Embedded derivative asset in convertible promissory note			0
Liability:
Forward Liability	0
Level 2 | Investment in Syros Pharmaceuticals, Inc. ("Syros")
Assets:
Investments	0
Level 2 | Investment in Enalare Therapeutics, Inc.
Assets:
Investments	0
Level 3
Assets:
Investments			0
Acquisition rights of Enalare Therapeutics, Inc.	8,125
Money market funds			0
Convertible promissory note			4,021
Embedded derivative asset in convertible promissory note			$ 962
Liability:
Forward Liability	4,063
Level 3 | Investment in Syros Pharmaceuticals, Inc. ("Syros")
Assets:
Investments	0
Level 3 | Investment in Enalare Therapeutics, Inc.
Assets:
Investments	$ 8,438